Overview

The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain vs the crisis of prescription opioid abuse. Pri-Med’s Strategies for Effective Pain Management in Clinical Practice curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including nonopioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse in order to optimally manage patients’ pain and medication use.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://www.opioidanalgesicrems.com/home.html for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Learning Objectives

  • Improve prescribers’ knowledge, competence and performance in the area of integrating opioids into individualized treatment plans to meet the needs of patients and managing those patients
  • Summarize counseling strategies, including counseling about the use of naloxone for opioid overdose
  • Recognize opioid use disorder and act appropriately to treat or refer those patients

Faculty

 

Charles E. Argoff, MD, FABPM

Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Albany, NY

Oscar A. de Leon-Casasola, MD

Professor of Anesthesiology and Medicine
Senior Vice-Chair
The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
Buffalo, NY

Katherine E. Galluzzi, DO, CMD, FACOFP

Professor and Chair
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Philadelphia, PA

Disclosures

The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Charles E. Argoff, MD, FABPM: Advisory Board for Amgen, BioDelivery Sciences International, Inc., Clexio Biosciences, Nevro, Neumentum, Regeneron Pharmaceuticals, SK Life Sciences, Teva Pharmaceuticals, and Tremeau Pharmaceuticals, Inc., and Vertex. Consulting for EnZen Therapeutics, Opioid PMR Consortium, and XGene Pharma. Contracted Research for AbbVie, Allergan, Amgen, Lilly, Lundbeck, and Teva. Services Provided for Promotional Purposes for Collegium. Speaker’s Bureau for AbbVie, Amgen, Biohaven, Lilly, Nevro, Redhill Pharma, and Teva.

Oscar A. de Leon-Casasola, MD: Advisory Board for Esteve Pharma, Heron Therapeutics, Medtronic, Tremeau Pharma.

Katherine E. Galluzzi, DO, CMD, FACOFP: No relevant financial relationships to disclose.

 

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.


CME Information

AMA PRA Category 1 Credits

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.


Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.


Designation Statement

This activity is approved for 1.08 contact hours of continuing education, which includes 0.16 hours of pharmacology.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

MOC Credit Information

Successful completion of this CME activity (“Strategies for Effective Pain Management in Clinical Practice”), which includes participation in the evaluation component, enables the participant to earn up to 3.5 Medical Knowledge & Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory (https://www.continuingcertification.org), Strategies for Effective Pain Management in Clinical Practice has met the requirements as a MOC Part II Self-Assessment Activity and MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II Self-Assessment Activity:
Physical Medicine and Rehabilitation

ABMS MOC Part II CME Activity:
Allergy and Immunology
Anesthesiology
Colon and Rectal Surgery
Family Medicine
Preventive Medicine
Psychiatry and Neurology
Radiology
Thoracic Surgery
Urology


State Licensure Requirements

This activity satisfies topic-specific CME/CE requirements (pain management, controlled substances, etc.) of many state licensing boards. Please check with your state’s licensing boards for specific requirements, and print this page as appropriate for documentation.

This activity is approved for Pain Management and Prescription of Opioids requirements from the Texas Medical Board/Board of Nursing, which may also satisfy the medical ethics and/or professional responsibility.


Commercial Supporter

Opioid Analgesic REMS Program Companies

Education Partner

Miller Medical Communications, LLC


Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.